{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/rosacea/diagnosis/diagnosis/","result":{"pageContext":{"chapter":{"id":"bd6d5455-d63e-5507-8bdd-028b338047cc","slug":"diagnosis","fullItemName":"Diagnosis","depth":2,"htmlHeader":"<!-- begin field 88332838-67f1-4672-b47a-c6b1814d73c9 --><h2>When should I suspect a diagnosis of rosacea?</h2><!-- end field 88332838-67f1-4672-b47a-c6b1814d73c9 -->","summary":"","htmlStringContent":"<!-- begin item 7185f81d-0cb1-4294-b4ce-1979146e4968 --><!-- begin field 903e5527-886c-423e-af56-8ab81ea5e203 --><p><strong>The clinical manifestations of rosacea often vary in nature and severity over time, and the diagnosis is usually made on the basis of clinical features alone.</strong></p><ul><li><strong>Make a diagnosis of rosacea if there is at least one 'diagnostic' or two 'major' clinical features (phenotypes) present:</strong><ul><li><strong>Diagnostic clinical features:</strong><ul><li>Phymatous changes — facial skin thickening due to fibrosis and/or sebaceous glandular hyperplasia. Most commonly affects the nose, where it may have a bulbous appearance (so-called rhinophyma). May be clinically inflamed (‘active’) or non-inflamed (‘fibrotic’ or ‘burnt out’).</li><li>Persistent erythema — persistent centrofacial redness that may periodically intensify in response to various <a class=\"topic-reference internal-reference\" href=\"/topics/rosacea/background-information/risk-factors/\">trigger factors</a>. Note: in darker skin phototypes (V and VI), erythema may be difficult to detect visually.</li></ul></li><li><strong>Major clinical features</strong> (which are not individually diagnostic):<ul><li>Flushing/transient erythema — a temporary increase in centrofacial redness, which may include sensations of warmth, heat, burning, and/or pain. Usually lasts for less than 5 minutes and may spread to the neck and chest. May be the initial presenting feature of rosacea.</li><li>Inflammatory papules and pustules — red papules and pustules, usually in the centrofacial area. Some may be larger and deeper, and may become nodules.</li><li>Telangiectasia — visible vessels in the centrofacial region, but not only in the alar area (side of nose).</li><li>Ocular manifestations.</li><li>Note: in darker skin phototypes (V and VI), erythema and telangiectasia may be difficult to detect visually.</li></ul></li><li><strong>Minor clinical features</strong> (which may be subjective and are not individually diagnostic):<ul><li>Burning sensation — an uncomfortable or painful feeling of heat, typically in the centrofacial region.</li><li>Stinging sensation — an uncomfortable or painful sharp, pricking sensation, typically in the centrofacial region.</li><li>Skin dryness sensation or appearance — skin that feels rough. May be tight, scaly, and/or itchy.</li><li>Oedema — localized facial swelling that may accompany or follow prolonged erythema or flushing. May be soft or firm (non-pitting), and may be transient or persistent.</li></ul></li></ul></li><li><strong>Suspect a diagnosis of ocular rosacea if:</strong><ul><li>There are eye symptoms such as:<ul><li>Eye discomfort, irritation, tearing, foreign body sensation, dryness, itching, photophobia, or blurred vision.</li></ul></li><li>There are eye signs of:<ul><li>Lid margin telangiectasia — visible vessels around the eyelid margins. Note: this may be difficult to detect visually in darker skin phototypes (V and VI).</li></ul></li><li>There is suspected:<ul><li>Blepharitis or acute lid infection (chalazion or hordeolum). See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/blepharitis/\">Blepharitis</a>, <a class=\"topic-reference external-reference\" href=\"/topics/meibomian-cyst-chalazion/\">Meibomian cyst (chalazion)</a>, and <a class=\"topic-reference external-reference\" href=\"/topics/styes-hordeola/\">Styes (hordeola)</a> for more information.</li><li>Conjunctivitis — inflammation of the mucous membranes lining the inner surface of the eyelids and bulbar conjunctiva. Typically associated with injection or vascular congestion and conjunctival oedema. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/conjunctivitis-infective/\">Conjunctivitis - infective</a> for more information.</li><li>Keratitis. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/red-eye/\">Red eye</a> for more information.</li><li>Anterior uveitis — inflammation of the iris and/or ciliary body. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/uveitis/\">Uveitis</a> for more information.</li></ul></li><li>Note: be aware that eye symptoms or signs may present with or without skin disease.</li></ul></li></ul><!-- end field 903e5527-886c-423e-af56-8ab81ea5e203 --><!-- end item 7185f81d-0cb1-4294-b4ce-1979146e4968 -->","topic":{"id":"907deb55-501c-50b0-9c07-5956c70cf201","topicId":"d6855039-5025-454d-b195-d4b0a3763978","topicName":"Rosacea ","slug":"rosacea","lastRevised":"Last revised in January 2021","chapters":[{"id":"a3d8bb8f-cf98-5320-abe8-71c7b0c3d604","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"a9c3b514-8e94-52d5-8de7-2caedcdd8ed3","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"efe24f29-88ad-5507-b4b5-ec00c54a404d","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"10634254-4474-5303-9337-e3682fd14514","slug":"changes","fullItemName":"Changes"},{"id":"1ad5ada5-1ed7-5223-b60c-122b20127e1e","slug":"update","fullItemName":"Update"}]},{"id":"832a95da-0571-5031-b437-3cc5568bc7fa","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"59d41997-63c3-57d4-8c29-c4655d090e7a","slug":"goals","fullItemName":"Goals"},{"id":"2c3bc0a5-be4b-5a98-a5d8-02e7cb85b9cb","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"f8c34a65-7879-5a21-87df-68739ba5d1f3","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"9f050a9b-10be-5d79-b662-0099ac611890","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"9fcdbb11-1f96-5ae9-aeec-617a9da55e12","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"538579d3-7620-5145-a70f-022ec13226ae","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d0b606da-7836-5c33-8390-23a6dad9e7bd","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"ed198aaf-1444-5590-ab74-c9fdff996b5e","slug":"definition","fullItemName":"Definition"},{"id":"df406671-3834-580f-836a-3c2428245359","slug":"prevalence","fullItemName":"Prevalence"},{"id":"be28c459-5653-506e-937c-5c4d2f7ceecd","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"bc98e144-7d7d-5fa2-97ad-7c1bd8526ca0","slug":"complications","fullItemName":"Complications"},{"id":"1a5cbcf6-2870-5a82-a207-8c8888f907d2","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"d654b61f-b47e-5123-b965-f806f0eb2e6d","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"bd6d5455-d63e-5507-8bdd-028b338047cc","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"30d3265f-84ec-5ac7-a410-bc11cd078ac9","slug":"assessment","fullItemName":"Assessment"},{"id":"e111154d-c82a-5292-b201-f4a12a8a4d17","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"e753e991-54fe-5ab5-96d2-124372f1292f","fullItemName":"Management","slug":"management","subChapters":[{"id":"0e7b3ebf-33f5-5b51-a9ab-81c8dda1332f","slug":"rosacea","fullItemName":"Scenario: Rosacea"}]},{"id":"602c95a0-f64e-593e-85c4-798ea728733b","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"e6e7bc13-b6bd-5b5e-b337-196c3291ee63","slug":"topical-treatments","fullItemName":"Topical treatments"},{"id":"c53198f5-f60b-5fb6-8767-9f9a275329f5","slug":"oral-antibiotics","fullItemName":"Oral antibiotics"}]},{"id":"0db34d3f-c02f-5b8f-8498-90541139bc2a","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"ca47aba9-e0da-5e0a-a1a2-46bfab6fe609","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"5c0a0103-4ed2-586f-8fbd-aaf6fe82f548","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"84966474-462f-592c-b43d-474d1ca89d52","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"bb2d8252-c981-52ba-9faf-d9e9450efe7c","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"f5e586ed-912a-51ab-b246-3a6f6c67e2d1","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"a60f4af9-1a6a-5a71-9310-2b3fe7d0cb92","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"40a50d91-c85e-5b2c-b283-ca2a9f30c6f0","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"d654b61f-b47e-5123-b965-f806f0eb2e6d","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"f5022be0-7e92-5ca3-b3a8-545b1300d8ef","slug":"basis-for-recommendation-302","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field 1205a4eb-6b93-4c96-ab4e-3bab59eff57a --><h3>Basis for recommendation</h3><!-- end field 1205a4eb-6b93-4c96-ab4e-3bab59eff57a -->","summary":null,"htmlStringContent":"<!-- begin item 3025800c-7b8c-4a69-9b09-ececafdd268a --><!-- begin field 3a927927-3d0e-4a3d-95a7-6c7ccb7bc5f1 --><p>The recommendations on diagnosis are largely based on the ROSacea COnsensus (ROSCO) international consensus publications <em>Rosacea treatment update: recommendations from the global ROSacea COnsensus (ROSCO) panel</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Schaller, 2017</a>], <em>Updating the diagnosis, classification and assessment of rosacea: recommendations from the global ROSacea COnsensus (ROSCO) panel</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Tan, 2017</a>], and <em>Recommendations for rosacea diagnosis, classification and management: update from the global ROSacea COnsensus 2019 panel</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Schaller, 2020</a>]; the US National Rosacea Society (NRS) expert committee publication <em>Standard classification and pathophysiology of rosacea</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Gallo, 2018</a>]; the American Acne and Rosacea Society (AARS) publication <em>Update on the management of rosacea from the American Acne and Rosacea Society (AARS)</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Del Rosso, 2019</a>]; the College of Optometrists clinical management guideline <em>Ocular rosacea</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">College of Optometrists, 2018</a>]; a systematic review of interventions for rosacea [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">van Zuuren, 2019</a>]; and expert opinion in review articles on rosacea [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Oge, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">van Zuuren, 2017</a>], on the epidemiology of rosacea [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Alexis, 2019</a>], and on the phenotype approach to classification [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Tan, 2018</a>].</p><ul><li>The information that there are multiple clinical manifestations of rosacea that may change over time is based on the ROSCO consensus publications [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Schaller, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Schaller, 2020</a>], the NRS publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Gallo, 2018</a>], the AARS publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Del Rosso, 2019</a>], and expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Tan, 2018</a>].</li><li>The information that the diagnosis of rosacea is usually made on the basis of clinical features alone is based on the ROSCO consensus publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Tan, 2017</a>].</li><li>The recommendation to make a diagnosis of rosacea based on the presence of diagnostic, major and/or minor clinical features is largely based on the ROSCO consensus publications [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Tan, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Schaller, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Schaller, 2020</a>], and the NRS publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Gallo, 2018</a>].<ul><li>The NRS publication notes there has been a change in the literature from a subtype to a phenotype classification for the diagnosis and management of rosacea. This has partly been in response to the fact a person may have more than one subtype co-existing, the potential for progression from one subtype to another, and the difficulty in assessing severity of different subtypes simultaneously and their response to interventions.</li><li>A systematic review of interventions for rosacea notes the phenotype approach should improve the accuracy of diagnosis, and improve patient-centred care [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">van Zuuren, 2019</a>]. This is supported by the ROSCO consensus publications that note that the subtype classification may not fully cover the full range of clinical presentations of rosacea [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Tan, 2017</a>], and skin clinical feature descriptions can help improve and standardize disease diagnosis and monitoring [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Schaller, 2020</a>]. In addition, expert opinion in a review article proposes that a phenotype approach may improve patient outcomes by targeting the clinical features that are most troublesome for the person [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Tan, 2018</a>].</li><li>The information on the clinical features that are diagnostic of cutaneous rosacea, and the criteria that at least one diagnostic or two major phenotypes are required for the diagnosis, are largely based on the ROSCO consensus publications [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Tan, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Schaller, 2020</a>].</li><li>The information that pathognomonic phymatous changes may be clinically inflamed or non-inflamed is based on a ROSCO consensus publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Schaller, 2017</a>].</li><li>The information that erythema and telangiectasia may be difficult to detect visually in people with darker skin phototypes is based on the ROSCO consensus publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Schaller, 2020</a>] and expert opinion in a review article, which notes that a delay in diagnosis may lead to inappropriate treatment, or uncontrolled progressive disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Alexis, 2019</a>].</li><li>The clinical details about flushing are also based on the NRS publication and expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Oge, 2015</a>].</li><li>The clinical details about oedema are based on the NRS publication, which notes this may be a result of postcapillary extravasation during inflammation.</li></ul></li><li>The information on the clinical features of ocular rosacea is largely based on the ROSCO consensus publications [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Schaller, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Schaller, 2020</a>], the College of Optometrists clinical management guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">College of Optometrists, 2018</a>], and expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Oge, 2015</a>].<ul><li>The information that eye symptoms or signs may present with or without skin disease is based on the ROSCO consensus publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Schaller, 2017</a>] and the NRS publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Gallo, 2018</a>].</li></ul></li></ul><!-- end field 3a927927-3d0e-4a3d-95a7-6c7ccb7bc5f1 --><!-- end item 3025800c-7b8c-4a69-9b09-ececafdd268a -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}